Exisulind, a selective apoptotic antineoplastic drug

Expert Opinion on Investigational Drugs

Volumn 10, Issue 10, 2001, Pages 1875-1882

  Goluboff, E T ^a  

^a NewYork Presbyterian Columbia University Irving Medical Center   (United States)

Author keywords

Apoptosis; Cancer; Exisulind; SAANDs

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; CISPLATIN; CP 461; CYCLIC GMP DEPENDENT PROTEIN KINASE; DOCETAXEL; DOXORUBICIN; GEMCITABINE; IRINOTECAN; NAVELBINE; PACLITAXEL; PLACEBO; PROSTATE SPECIFIC ANTIGEN; RETINOIC ACID; SULINDAC SULFONE; TRASTUZUMAB; UNCLASSIFIED DRUG;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLADDER CANCER; BLOOD DISEASE; BREAST CANCER; CANCER; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER TISSUE; CELL DEATH; CLINICAL TRIAL; COLON CANCER; COLON POLYP; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CLASSIFICATION; DRUG HALF LIFE; DRUG POTENTIATION; DRUG SCREENING; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; DYSPEPSIA; ENZYME ACTIVATION; FAMILIAL COLON POLYPOSIS; FATIGUE; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MOUSE; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PROSTATE CANCER; PROSTATECTOMY; RANDOMIZED CONTROLLED TRIAL; RAT; RECTUM POLYP; RODENT; SOLID TUMOR; TUMOR GROWTH;

EID: 0034774026     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.10.10.1875     Document Type: Article

References (39)

1. Exisulind induction of apoptosis involves guanosine 3′,5′-monophosphate phosphodiesterase inhibition, protein kinase g activation and attenuated β-catenin
2. 2-terminal kinase 1
3. Protein kinase G activates the JNK1 pathway via phosphorylation of MEKK1
4. Overexpression of cGMP phosphodiesterase (cG-PDE) in colonic neoplasias compared to normal mucosa
5. Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction
6. Sulindac derivatives inhibit growth and induce apoptosis in human prostate cancer cell lines
7. Synergistic effects of new chemopreventative agents and conventional cytotoxic agents against human lung cancer cell lines
8. Effects of sulindac and its metabolites on growth and apoptosis in human mammary epithelial and breast carcinoma cell lines
9. Exisulind, a novel proapoptotic drug, inhibits rat urinary bladder tumorigenesis
10. Sulindac and its metabolites sulindac sulfide and sulindac sulfone induce apoptosis in human cervical cancer cells
11. Sulindac and exisulind exhibit a significant antiproliferative effect and induce apoptosis in human hepatocellular carcinoma cell lines
12. Antineoplastic effects of exisulind (Prevatac) and its analogs on leukemia and myeloma cell lines
13. Cyclic GMP phosphodiesterase (cG-PDE): Overexpression in human pancreatic carcinomas and a target for selective apoptotic antineoplastic drugs
14. Phosphodiesterase 5 overexpression in human non-small cell lung tumors compared to normal bronchial epithelium
15. Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels
16. Inhibition of mammary carcinogenesis in rats by sulfone metabolite of sulindac
17. Exisulind (sulindac sulfone) suppresses growth of human prostate cancer in a nude mouse xenograft model by increasing apoptosis
18. Inhibition of 4-(methylnitrosamino)-1- (3-pyridyl)-1- butanone-induced mouse lung tumour formation by FGN-1 (sulindac sulfone)
19. Synergistic effects of exisulind with conventional chemopreventive and therapeutic agents against human lung cancer cells in vitro and in vivo
20. Exisulind inhibits cell growth, induces apoptosis, and has synergy with herceptin and taxotere in breast cancer cells
21. Exisulind and docetaxel (Taxotere®) combination prolongs survival in orthotopic human non-small cell lung cancer rat model
22. Efficacy of exisulind and docetaxel combination in a orthotopic human non-small cell lung cancer rat model involves apoptosis induction and angiogenesis inhibition
23. Exisulind and docetaxel combination prolongs survival in orthotopic human non-small cell lung cancer rat model
24. Apoptosis in human prostate cancer cells shows enhanced sensitivity to taxol in the presence of exisulind
25. Exisulind enhances the growth inhibitory effects of gemcitabine and vinorelbine on human lung cancer cell lines
26. Enhancement of chemotherapeutic drug toxicity to human tumour cells in vitro by a subset of non-steroidal anti-inflammatory drugs (NSAIDS)
27. CP461 induces apoptosis and growth inhibition of breast cancer cells independent of HER2/neu receptor expression
28. CP-461 enhances the antitumor effects of paclitaxel in subcutaneously implanted human mammary tumor (MX-1) xenografts in nude mice
29. CP-461 is active alone and in combination with gemcitabine, vinorelbine, or irinotecan in non-small cell lung cancer cell lines
30. Effects of exisulind on human liver cytochrome p450 enzymes: Inhibition, induction and metabolism studies
31. The effect of exisulind on rectal adenomas in adults with familial adenomatous polyposis
32. Sulindac sulfone induced regression of rectal polyps in patients with familial adenomatous polyposis
33. A Phase I trial of exisulind (sulindac sulfone, FGN-1) as a chemopreventative agent in patients with familial adenomatous polyposis
34. Exisulind prevents adenoma formation in familial adenomatous polyposis (FAP)
35. Exisulind, a pro-apoptotic drug, prevents new polyp formation in patients with familial adenomatous polyposis
36. Safety and efficacy of exisulind for treatment of recurrent prostate cancer after radical prostatectomy
37. A Phase I study of exisulind in previously treated patients with lung cancer
38. A Phase I and pharmacologic (PK) study of exisulind (E) combined with taxotere (T) in patients with advanced cancer
39. Phase I clinical and pharmacokinetic (PK) trial of the novel pro-apoptotic compound CP-461 administered orally on a continuous twice-daily schedule to patients with advanced malignancies